Ishita Drugs & Industries reported a 24% decline in standalone net profit to ₹23.02 lakh in the quarter ended June 2026, compared to ₹30.23 lakh in the corresponding quarter of the previous year. According to the company's unaudited financial results approved by the Board on August 8, 2026, this represents a significant drop in the company's bottom-line performance during the first quarter of fiscal 2026. The Board of Directors approved the results following a limited review by statutory auditors Jaymin Shah & Associates.
The company's revenue from operations declined by 41.67% to ₹314.53 lakh in Q1 FY2026, down from ₹540.05 lakh recorded in the same quarter of the previous financial year. As reported in the company's financial results, this substantial revenue decline indicates challenging market conditions or operational issues that impacted the company's top-line performance during the quarter. The company's total income stood at ₹318.16 lakh, down from ₹549.16 lakh in Q1FY25, reflecting the overall contraction in business activity. The debt-equity ratio remains at 0.00, indicating a debt-free balance sheet, which provides flexibility for the planned facility upgrades without immediate pressure on interest servicing.
Despite the revenue decline, the company demonstrated effective cost control with total expenses falling by approximately 43% compared to the previous year. Finance costs reduced significantly to ₹0.47 lakh from ₹2.33 lakh in Q1FY25, contributing positively to the bottom line. However, other expenses remained relatively sticky at ₹72.70 lakh, only slightly higher than the ₹66.83 lakh recorded in Q1FY25, suggesting fixed overheads are not scaling down proportionally with revenue. The operating profit margin (OPM) stood at 9.84% in the June 2026 quarter, compared to 6.48% in the corresponding quarter of the previous year, indicating better cost management despite the revenue challenges. Cost of material consumed decreased substantially to ₹138.45 lakh from ₹379.59 lakh in the previous year quarter, indicating better input cost management or lower production volumes.
Employee benefit expense increased to ₹37.45 lakh from ₹33.60 lakh in Q1FY25, while other income contracted to ₹3.63 lakh from ₹9.11 lakh year-on-year. Tax expense stood at ₹7.00 lakh compared to ₹8.50 lakh in the corresponding quarter of the previous financial year. These figures demonstrate the company's ability to manage costs effectively during a challenging period, though the revenue decline offset these savings. Depreciation & Amortisation increased to ₹4.98 lakh from ₹2.75 lakh in Q1FY25, reflecting ongoing capital investments in the business.
Beyond financial performance, the Board addressed key governance matters during its August 8, 2026 meeting. The Board approved the re-appointment of Mrs. Abha Agrawal (DIN 01589479) as a Non-Executive Non-Independent Director, notwithstanding her attaining the age of 75 years, subject to shareholder approval at the upcoming Annual General Meeting. Additionally, based on recommendations from the Audit Committee and Nomination and Remuneration Committee, the Board accepted the revised remuneration proposal for Mr. Sumit Agrawal, Chief Financial Officer. The company is currently undertaking significant infrastructure upgrades to comply with Revised Schedule M regulations, having spent ₹435 lakh on renovating existing buildings and constructing new blocks, with capital contracts worth approximately ₹565 lakh issued for various utilities and equipment. Managing Director Jagdish Agrawal informed the Board that construction of a new block for warehouse accommodation has been completed, while civil work for extending existing buildings is ongoing.
